研究单位：[1]CSPC ZhongQi Pharmaceutical Technology Co., Ltd.[2]Beijing Tongren Hospital,Beijing,Beijing,China,100000[3]Cancer Institute and Hospital, Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[4]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[5]Gansu Province Tumor Hospital,Lanzhou,Gansu,China,730000[6]Sun Yat-Sen University Cancer Center,Guangzhou,Guangdong,China,510080[7]Henan Province Tumor Hospital,Zhengzhou,Henan,China,450003[8]Jiangsu province tumor hospital,Nanjing,Jiangsu,China[9]Cancer Hospital of Fudan University,Shanghai,Shanghai,China,200032[10]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610041[11]Tianjin Medical University Cancer Institute and Hospital,Tianjin,Tianjin,China,300600[12]Tianjin People's Hospital,Tianjin,Tianjin,China,300600[13]The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650032[14]Zhejiang Provincial People''s Hospital,Hangzhou,Zhejiang,China,310022
研究目的：
This is a single-arm, open-label, multicenter study designed to evaluate the preliminary antineoplastic activity, safety and tolerability of HA121-28 tablets administered orally in patients with medullary thyroid cancer (MTC).
